Cormorant Asset Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Cormorant Asset Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-82,988	Closed	-$1.85M	–	62
2018 Q1	$1.85M	Sell	82,988 -284,235	-77%	-$6.31M	0.14%	48
2017 Q4	$4.68M	Buy	367,223 +7,485	+2%	+$110K	0.49%	38
2017 Q3	$5.61M	Hold	359,738	–	–	0.99%	30
2017 Q2	$5.05M	Sell	359,738 -75,238	-17%	-$1.61M	0.84%	33
2017 Q1	$9.56M	Buy	+434,976	New	+$9.22M	1.39%	27

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cormorant Asset Management's JNCE Position: Q2 2018 in Review

Cormorant Asset Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2018, closing a stake of 82,988 shares — an estimated $1.85M sold.

Cormorant Asset Management first reported a position in JNCE in Q1 2017 and held it in 5 quarters. The position peaked at $9.56M in Q1 2017. 83 funds tracked by Wall St. Rank hold JNCE as of Q2 2018.

Cormorant Asset Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
Cormorant Asset Management sold 82,988 Jounce Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $1.85M.
Cormorant Asset Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 5 quarters.
Cormorant Asset Management's Jounce Therapeutics, Inc. Common Stock position peaked at $9.56M in Q1 2017.
83 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2018.

Based on Cormorant Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.